Cleo Diagnostics advances its FDA validation program, bringing a promising blood test closer to clinical use
Melbourne, Australia, 13 July 2026 – Early detection can make a significant difference in the fight against ovarian cancer, one of the most difficult cancers to diagnose in its early stages. Because symptoms are often vague and existing diagnostic methods have limitations, researchers and healthcare companies continue searching for faster and more accurate ways to identify the disease. Australian biotechnology company Cleo Diagnostics is now moving closer to that goal as it advances an important stage of its regulatory journey in the United States.
The company recently entered the analytical validation phase of its Food and Drug Administration, or FDA, approval process. This stage is designed to confirm that the test performs consistently and accurately before it can be submitted for regulatory review. It represents one of the final technical steps before clinical data is analyzed and included in the company’s FDA submission.
Cleo Diagnostics is developing a simple blood test that aims to help doctors determine whether an ovarian mass is likely to be cancerous before surgery. Current diagnostic methods often rely on imaging, blood markers, and clinical assessment, but these approaches do not always provide clear answers. A more accurate blood test could help physicians make better treatment decisions and ensure that patients receive the most appropriate care at an earlier stage.
The company’s technology is built around a patented biomarker known as CXCL10. According to Cleo Diagnostics, this biomarker is found at higher levels in ovarian cancer while remaining much lower in non-cancerous conditions. Researchers believe this difference may improve the ability to distinguish between benign and malignant ovarian masses using a simple blood sample.
Before reaching this latest milestone, Cleo completed patient recruitment and sample collection for its pivotal United States clinical trial. The study enrolled 624 women across 19 medical centers and collected more than 500 blood samples, providing the clinical data needed for the next phase of testing. This achievement allowed the company to move from patient recruitment into laboratory validation and clinical sample analysis.
Analytical validation focuses on proving that a diagnostic test delivers reliable and repeatable results under different testing conditions. Scientists evaluate whether the test maintains accuracy, precision, and consistency before it can be used to analyze patient samples for regulatory approval. Completing this stage is essential before the company can submit its evidence package to the FDA through the 510(k) clearance pathway.
To support this work, Cleo Diagnostics has partnered with Bio Techne, a global life sciences company that will help manufacture the test kits used during validation. The partnership is intended to ensure that the test can be produced consistently while meeting regulatory quality standards. Manufacturing readiness is considered an important part of preparing any medical diagnostic product for commercial use.
The broader healthcare industry continues to invest heavily in blood-based diagnostics because they can offer faster, less invasive, and more accessible testing compared with many traditional procedures. In diseases such as ovarian cancer, where early diagnosis remains difficult, improved diagnostic tools could help doctors identify high-risk patients sooner and potentially improve treatment outcomes.
Although several regulatory and clinical steps remain before the test becomes commercially available, the company’s recent progress reflects the steady advancement of modern diagnostic technologies. Every completed milestone reduces development risk and moves the product closer to possible clinical adoption.
As healthcare increasingly shifts toward precision medicine and earlier disease detection, innovations like blood-based cancer diagnostics may become an important part of routine patient care. Cleo Diagnostics’ latest progress highlights how scientific research, clinical testing, and regulatory validation continue working together to improve the future of women’s health and cancer diagnosis.